The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.
 
Masafumi Ikeda
Consulting or Advisory Role - NanoCarrier
Speakers' Bureau - Abbott Diagnostics; Bayer Yakuhin; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Guerbet; Kyowa Hakko Kirin; Merck Serono; Novartis; Takeda; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boston Biomedical (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Satoshi Shimizu
No Relationships to Disclose
 
Tosiya Sato
Honoraria - Lilly Japan
Consulting or Advisory Role - Sumitomo Group
 
Manabu Morimoto
Honoraria - Bayer; Dainippon Sumitomo Pharma; Eisai; Nippon Kayaku
Research Funding - Bayer (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Shionogi (Inst); Yakult Pharmaceutical (Inst)
 
Yoshitaka Inaba
Consulting or Advisory Role - Eisai; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Daiichi Sankyo; Eisai; Taiho Pharmaceutical
 
Yasushi Kojima
Stock and Other Ownership Interests - Chugai Pharma; Takeda
Speakers' Bureau - Chugai Pharma; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Kyowa Hakko Kirin (Inst)
 
Atsushi Hagihara
Speakers' Bureau - Bayer; Dainippon Sumitomo Pharma; MSD; Otsuka
 
Masatoshi Kudo
No Relationships to Disclose
 
Shoji Nakamori
No Relationships to Disclose
 
Shuichi Kaneko
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Toray Industries
Speakers' Bureau - Astellas Pharma; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Toray Industries
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
Expert Testimony - Bayer
 
Rie Sugimoto
Honoraria - Abbott Diagnostics; AstraZeneca; Daiichi Sankyo
Speakers' Bureau - Abbott Diagnostics
Research Funding - Boehringer Ingelheim (Inst); Kyowa Hakko Kirin (Inst)
 
Toshiyuki Tahara
No Relationships to Disclose
 
Takumi Ohmura
Honoraria - Century Medical; Daiichi Sankyo; Eisai; Japan Blood Products Organization
Speakers' Bureau - Bayer; Dainippon Sumitomo Pharma; Piolax
 
Kohichiroh Yasui
No Relationships to Disclose
 
Keiko Sato
Honoraria - Lilly Japan
Consulting or Advisory Role - Sumitomo Chemical; Sumitomo Group
 
Hiroshi Ishii
Honoraria - Ajinomoto; Bayer; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Torii Pharmaceutical
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Nippon Kayaku; Ono Pharmaceutical; Sandoz; Sanofi; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Eisai; Fujifilm; GlaxoSmithKline; J-Pharma; Janssen; Kowa; Kyowa Hakko Kirin; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly Japan; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)